Edit

Lys Therapeutics

https://lystherapeutics.com/

Lys Therapeutics is a biotechnology company pioneering a breakthrough approach to treat patients suffering from neurodegenerative or neurovascular disorders. Its main drug is a first-in-class monoclonal antibody, Glunozumab, displaying an exclusive and groundbreaking mechanism of action. It is demonstrated that one endogenous protease called tissue plasminogen activator (tPA) is implicated in the pathophysiology of neurological diseases such as multiple sclerosis, Parkinson’s disease, stroke and other neurodegenerative disorders through its overexpression and binding to NMDA receptors (NMDAr) present on vascular endothelial cells and regulating the blood brain barrier (BBB) function / dysfunction. The overactivation of vascular NMDAr is triggering a strong increase of the permeability of the BBB allowing the transmigration of toxic immune cells to the brain parenchyma leading to neuroinflammation, ultimately causing neurodegeneration. By blocking the tPA-NMDAr interaction inside the blood vessels, Glunozumab is restoring both NMDAr and blood-brain barrier physiological functioning (no perturbation of basal function), blocking both neuroinflammatory and neurodegenerative processes. This unique mechanism of action implies that Glunozumab does not need to cross the BBB to act on the central nervous system, which is a distinctive feature for the treatment of neurological diseases. Targeting major societal impact, the clinical development of Glunozumab biotherapy is of priority for Lys Therapeutics, as a potential game changer for patients suffering from neurological disorders with high unmet medical needs. More information on lystherapeutics.com